Immuno Oncology Diagnosis Global Market Report 2026

Immuno-oncology diagnosis involves the identification and evaluation of cancer-associated biomarkers and immune system responses to better understand the interaction between tumors and the immune system. It assists in determining cancer characteristics, supports precise diagnosis, and helps guide treatment planning. Immuno-oncology diagnostics facilitate patient stratification, improve therapy selection, and enable monitoring of treatment response, contributing to better overall cancer care outcomes.

The primary product types of immuno-oncology diagnosis include assays, kits, reagents, instruments, and software. Assays are diagnostic tests designed to identify, quantify, and evaluate biological markers associated with immune responses and cancer-related conditions. These products employ technologies including polymerase chain reaction, next-generation sequencing, immunohistochemistry, flow cytometry, and other advanced technologies. They are used in cancer diagnosis, research, drug development, and other applications, serving hospitals, diagnostic laboratories, academic and research institutes, and pharmaceutical and biotechnology companies.

Tariffs are influencing the immuno oncology diagnosis market by increasing the cost of imported diagnostic reagents, sequencing platforms, and advanced biomarker detection kits required for cancer diagnostics and research activities. This is creating cost pressures across high-value segments such as next-generation sequencing, flow cytometry, and immunohistochemistry technologies, with hospitals, diagnostic laboratories, and biotechnology companies encountering higher procurement expenses. Import-dependent regions, particularly across Asia-Pacific and parts of Europe, are also experiencing delays in accessing advanced diagnostic technologies alongside supply chain disruptions. At the same time, tariffs are encouraging domestic production of diagnostic kits, regional manufacturing of reagents, and strategic technology transfer partnerships, strengthening long-term resilience and innovation within cancer diagnostics ecosystems.

The immuno oncology diagnosis market research report is one of a series of new reports from The Business Research Company that provides immuno oncology diagnosis market statistics, including immuno oncology diagnosis industry global market size, regional shares, competitors with a immuno oncology diagnosis market share, detailed immuno oncology diagnosis market segments, market trends and opportunities, and any further data you may need to thrive in the immuno oncology diagnosis industry. This immuno oncology diagnosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The immuno oncology diagnosis market size has grown strongly in recent years. It will grow from $13.8 billion in 2025 to $15.15 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to rising global cancer incidence rates, increasing adoption of targeted cancer therapies, expansion of hospital based diagnostic laboratories, growing use of immunohistochemistry techniques in oncology, improvements in biomarker discovery technologies.

The immuno oncology diagnosis market size is expected to see strong growth in the next few years. It will grow to $22.16 billion in 2030 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to increasing demand for personalized cancer immunotherapy, expansion of liquid biopsy and non invasive diagnostics, rising adoption of ai driven diagnostic platforms, growth in precision medicine and companion diagnostics, increasing investment in oncology research and clinical trials. Major trends in the forecast period include liquid biopsy based immuno-oncology diagnostic assays for early cancer detection and monitoring, multiplex immune profiling platforms for tumor microenvironment characterization, companion diagnostic kits for personalized cancer immunotherapy selection, high sensitivity flow cytometry based immune cell analysis for cancer stratification, ai enabled digital pathology software for immuno-oncology biomarker interpretation.

The rising global burden of cancer is anticipated to drive the growth of the immuno-oncology diagnosis market in the forecast period. Cancer is a medical condition involving the uncontrolled multiplication and progression of abnormal cells, which can infiltrate nearby tissues and metastasize to other areas of the body, affecting normal physiological functions. The incidence of cancer is increasing due to the growing elderly population, as aging contributes to the accumulation of genetic alterations and cellular damage, thereby increasing the likelihood of tumor formation. Immuno-oncology diagnosis facilitates cancer care by supporting biomarker detection, immune system profiling, and precision oncology testing, which are essential for developing personalized and targeted cancer treatment approaches, improving therapeutic effectiveness, patient outcomes, and clinical decision-making. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, global cancer cases were projected to exceed 35 million new cases by 2050, representing a 77% rise compared with the estimated 20 million cases recorded in 2022. Therefore, the increasing global prevalence of cancer is driving the growth of the immuno-oncology diagnosis market.

Key companies operating in the immuno-oncology diagnosis market are focusing on developing innovative solutions, such as AI-enabled multimodal immune profiling tests, to enhance precision cancer diagnosis, improve treatment response prediction, and support personalized immunotherapy decision-making. AI-enabled multimodal immune profiling tests are advanced diagnostic solutions that use artificial intelligence to analyze multiple biological data types, including genomic, proteomic, and immune biomarkers, to evaluate immune system responses and guide personalized cancer treatment decisions. For example, in November 2024, Tempus AI, Inc., a US-based artificial intelligence and precision medicine company, launched the Immune Profile Score (IPS) algorithmic test, an AI-enabled multimodal immune profiling test. It is designed to improve the evaluation of immune response patterns and support more informed immuno-oncology treatment decisions for cancer patients. The IPS test is a multimodal biomarker assay that integrates DNA and RNA sequencing insights with clinical and molecular data to generate a predictive immune response score ranging from 0 to 100.

In July 2025, Alden Scientific, a US-based research institute and health technology company, acquired Oncimmune Germany GmbH for an undisclosed amount. With this acquisition, Alden Scientific intended to reinforce its global position in precision medicine by expanding its expertise in immune profiling, autoantibody biomarker discovery, and multi-omics analytics, while obtaining access to Oncimmune's ImmunoINSIGHTS platform and its extensive antigen library containing more than 9,000 human and multi-species antigens. Oncimmune Germany GmbH is a Germany-based company providing immuno-oncology diagnostics, with expertise in biomarker discovery, immune profiling, and immunodiagnostic services.

Major companies operating in the immuno oncology diagnosis market report are Roche Diagnostics International AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Merck KGaA, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Bio-Techne Corporation, Natera Inc., Caris Life Sciences Inc., Myriad Genetics Inc., NeoGenomics Inc., Guardant Health Inc., Promega Corporation, Takara Bio Inc., Bioneer Corporation, Vazyme Biotech Co. Ltd., Exact Sciences Corporation, Hologic Inc., Becton Dickinson and Company

North America was the dominating region in the immuno oncology diagnosis market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the immuno oncology diagnosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the immuno oncology diagnosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The immuno-oncology diagnosis market consists of revenues earned by entities by providing services such as biomarker testing, molecular diagnostics, immunohistochemistry, flow cytometry, next-generation sequencing, companion diagnostics, and tumor profiling solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The immuno-oncology diagnosis market also includes sales of biomarker panels, companion diagnostics, molecular profiling tools, and digital pathology systems. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Immuno Oncology Diagnosis Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses immuno oncology diagnosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for immuno oncology diagnosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The immuno oncology diagnosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product Type: Assays; Kits; Reagents; Instruments; Software
• 2) By Technology: Polymerase Chain Reaction; Next Generation Sequencing; Immunohistochemistry; Flow Cytometry; Other Technologies
• 3) By Application: Cancer Diagnosis; Research; Drug Development; Other Applications
• 4) By End User: Hospitals; Diagnostic Laboratories; Academic And Research Institutes; Pharmaceutical And Biotechnology Companies
• Subsegments:
• 1) By Assays: Protein Biomarker Assays; Genomic Biomarker Assays; Multiplex Immunoassays; Companion Diagnostic Assays; Tumor Mutation Detection Assays; Immune Profiling Assays; Circulating Tumor Cell Assays; Liquid Biopsy Assays; Cell Based Functional Assays; Spatial Biology Assays
• 2) By Kits: Sample Preparation Kits; Nucleic Acid Extraction Kits; Biomarker Detection Kits; Immunohistochemistry Kits; Flow Cytometry Kits; Polymerase Chain Reaction Kits; Sequencing Library Preparation Kits; Tumor Profiling Kits; Companion Diagnostic Kits; Cell Isolation Kits
• 3) By Reagents: Antibodies Reagents; Staining Reagents; Detection Reagents; Buffer Reagents; Fluorescent Labeling Reagents; Enzyme Substrate Reagents; Cell Culture Reagents; Molecular Probe Reagents; Contrast Enhancement Reagents; Blocking Reagents
• 4) By Instruments: Flow Cytometry Instruments; Digital Pathology Instruments; Sequencing Instruments; Polymerase Chain Reaction Instruments; Microscopy Instruments; Immunoassay Analyzers; Slide Scanning Instruments; Cell Imaging Instruments; Automated Sample Preparation Instruments; Biomarker Analysis Instruments
• 5) By Software: Bioinformatics Software; Clinical Decision Support Software; Image Analysis Software; Data Management Software; Sequencing Analysis Software; Laboratory Information Management Software; Digital Pathology Software; Biomarker Interpretation Software; Artificial Intelligence Diagnostic Software; Cloud Based Analytics Software
• Companies Mentioned: Roche Diagnostics International AG; Thermo Fisher Scientific Inc.; Abbott Laboratories; Siemens Healthineers AG; Merck KGaA; Agilent Technologies Inc.; Illumina Inc.; Bio-Rad Laboratories Inc.; QIAGEN N.V.; Bio-Techne Corporation; Natera Inc.; Caris Life Sciences Inc.; Myriad Genetics Inc.; NeoGenomics Inc.; Guardant Health Inc.; Promega Corporation; Takara Bio Inc.; Bioneer Corporation; Vazyme Biotech Co. Ltd.; Exact Sciences Corporation; Hologic Inc.; Becton Dickinson and Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.